Table 1 Inclusion and exclusion criteria

From: Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant

Inclusion

 Women with a proven BRCA1 and/or BRCA2 mutation

 With≥2 synchronous or metachronous tumor localizationsa

 Tumor material available for next generation sequencing analysis (obtained by fine needle aspiration, histological biopsy or surgical excision)

 One of the 4 clinical scenarios:

1. Breast cancer and ovarian cancer

2. Breast cancer and second other tumor

3. Ovarian cancer and second other tumor

4. Breast cancer, ovarian cancer, and third or additional other tumor localizations

Exclusion criteria for ‘other tumor localization’

 Hematological malignancies

 Dermatological malignancies (ie. melanomas, basal cell carcinomas)

 Ipsilateral lymph node metastases in the presence of breast cancer

 Premalignant lesions, such as ductal carcinoma in situ

 Contralateral breast cancer or second ipsilateral breast cancer, except in the presence of a third tumor localization

 Peritoneal tumor localization in the presence of ovarian cancer

If reported that the ovarian cancer was growing per continuum into the peritoneal cavity

Confining to the ipsilateral adnexa

  1. aIsolated site of invasive cancer as diagnosed by radiological examination, intra-operatively or during pathological examination.
Back to article page